![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Peregrine Pharmaceuticals Announces Third Quarter Financial Results
Peregrine Pharmaceuticals Announces Third Quarter Financial Results
March 15, 2005
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company with a broad portfolio of products under development, announced financial results for the third quarter ended Jan. 31, 2005. The company reported a net loss of $3,744,000 or $0.03 per share, basic and diluted, for the quarter ended Jan. 31, 2005. This compares to a net loss of $4,137,000 or $0.03 per share, basic and diluted, for the same period last year.
Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=da510a28e21f29bb&cat=6dcd932030878143)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct